in vitro [8], clinical data including Bangladesh regimen experience support its efficacy [7, 9, 10], and for some patients (as in our case) clofazimine represents the only effective drug, exclusion of clofazimine from salvage therapy would greatly limit treatment efficacy. Patients due to receive a regimen with QT prolonging drugs (i.e. bedaquiline, delamanid, clofazimine and moxifloxacin) alone or in combination should receive ECG and electrolytes monitoring before and during treatment, so as not to lose therapeutic benefit. If QTc prolongation above 500 ms occurs, one of the QTc prolonging drugs should be promptly discontinued.

First case, concerns and challenges of treatment of severe XDR-TB with both delamanid and bedaquiline

Marina Tadolini1,7, Rangjung Dolma Lingtsang 2,7, Simon Tiberi3,7, Martin Enwerem4,7, Tsetan Dorji Sadutshang2, Rosella Centis5 and Giovanni Battista Migliori 5

1Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. 2Delek Hospital, Dharamshala, India. 3Division of Infection, Barts Health NHS Trust, London, UK. 4Amity Health Consortium, Johannesburg, South Africa. 5Fondazione S. Maugeri, IRCCS, Care and Research Institute, Tradate, Italy. 7Public Health Consulting Group, Lugano, Switzerland. 7These authors contributed equally.

Correspondence: Giovanni Battista Migliori, Fondazione S. Maugeri, Care and Research Institute, Via Roncaccio 16, 21049, Tradate, Italy. E-mail: giovannibattista.migliori@fsm.it

Received: Aug 03 2016 | Accepted: Aug 04 2016

Conflict of interest: None declared.

References
1 Tadolini M, Lingtsang RD, Tiberi S, et al. First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline. Eur Respir J 2016; 48: 935–938.
2 D’Ambrosio L, Tadolini M, Centis R, et al. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. Int J Infect Dis 2015; 32: 156–160.
3 Esposito S, D’Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811–815.
4 Choudhri SH, Harris L, Butany JW, et al. Clofazimine induced cardiotoxicity – a case report. Lepr Rev 1995; 66: 63–68.
5 de Carsalade GY, Wallach D, Spindler E, et al. Daily multidrug therapy for leprosy; results of a fourteen-year experience. Int Lepr Other Mycobact Dis. 1997; 65: 37–44.
6 Jarand J, Davis JP, Cowie RL, et al. Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest 2016; 149: 1285–1293.
7 Hwang TJ, Dotsenko S, Jafarov A, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 2014; 4: e004143.
8 Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114–3120.
9 World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis (2016 update). Document WHO/HTM/TB 2016.04, Geneva, World Health Organization, 2016.
10 Sotgiu G, Tiberi S, D’Ambrosio L, et al. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503–1507.

Tuberculosis prevention must integrate technological and basic care innovation

To the Editor:

ALBERT et al. [1] advocate for a multipronged approach in rolling out new diagnostic technology for tuberculosis (TB), stating “diagnostic tests alone, if not implemented with a comprehensive package of accompanying tools and within the context of a strengthened health system, may fail to demonstrate the expected benefit”. This is a lesson learned from those who have walked this path before us; one should not be too complacent to ignore basic strategies in the face of escalating technological advances in our field.
A telling example from the history of TB research and development serves as a potent reminder that technological innovation is ineffective in isolation. In 1917, due to the First World War, the Dutch company, Royal Philips, began developing X-ray equipment following supply chain cuts from Germany. Royal Philips eventually developed a portable X-ray capable of high-quality lung tissue images. In 1932, Royal Philips began TB screening among their staff, then their families, and eventually the entire populous of the city of Eindhoven (figure 1). This community-wide screening programme helped reduce TB rates in Eindhoven. By the 1940s, Eindhoven had less than half the TB incidence of cities like Amsterdam, Utrecht and Haarlem [2]. Remarkably, this dramatic reduction preceded the availability of antimicrobials. Treatment was a strict regimen of rest, diet, exercise and fresh air. Without lifestyle and dietary innovations, new diagnostic technologies such as radiography would have been ineffectual in controlling TB.

A hundred years on, the global TB epidemic persists and the innovative research and development community is struggling to deal with the increasing prevalence of drug-resistant TB. This calls for a re-visit to these basic innovations, with a greater focus on prevention of acquisition of infection and progression from latent to active disease. Whilst there are parallels between the TB epidemics of a hundred years ago and the present day, a significant difference is the nature of epidemiological transition and rapid urbanisation, driving the coexistence of infectious and non-communicable diseases, now occurring particularly in low- and middle-income countries. Basic and integrated innovations that address shared risk factors for TB and emerging non-communicable diseases are needed to improve overall health profiles. Nutritional and behavioural innovations that address exposures such as alcohol abuse, tobacco smoke, cooking fuels, diabetes and vitamin D deficiency, in addition to interventions in the built and natural environment, are going to become even more important. Clinicians at the frontlines of TB care in the developing world are often left trying to implement antimicrobial therapy in contexts of dense urban overcrowding, food insecurity and air pollution. Population growth and climate change are further exacerbating the global TB burden. Rolling out technological innovations in the absence of adequate nutrition and basic patient support services could very well serve the rise of drug-resistant TB.

In the contemporary TB research landscape, “innovation” has become almost synonymous with vaccine, biomarker and drug discovery. However, any of these technological innovations will require appropriate implementation within the context of the community they are targeted at. The coexistence of a variety of underlying morbidities, each an independent risk factor for TB, also indicates that the research community developing new technologies must test these technologies in a variety of populations and co-morbidity.
Despite this need for understanding the inter-relationship of co-morbidities, interventional research studies often exclude the majority of these individuals who are most at risk. This includes pregnant women and children, and persons with diabetes and HIV infection. Often-insufficient demographic information is captured to analyse the effect of contextual factors such as alcohol abuse, smoke exposure, and nutritional deficiencies on research outcomes. If taken into account, an integrated treatment approach addressing nutritional, behavioural and social interventions together with the new technology could then be assessed.

New technology alone cannot solve the TB epidemic. Innovative, integrated and community-driven solutions, which apply a primary health care approach, and are not purely based on technological innovation, will be required to stop the persistence of TB.

Without societal, lifestyle and dietary innovations, new technologies will be ineffectual in stopping tuberculosis http://ow.ly/IgY3303bgdU

Paul H. Mason 1,2, Tolu Oni3, Maarten M.J.W. van Herpen4 and Anna K. Coussens5

1Centre for Values, Ethics and the Law in Medicine, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia. 2Dept of Anthropology, Macquarie University, Sydney, Australia. 3Division of Public Health Medicine, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 4Philips Africa Innovation Hub, Nairobi, Kenya. 5Division of Medical Microbiology, Dept of Pathology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Correspondence: Paul H. Mason, Woolcock Institute of Medical Research, University of Sydney, 431 Glebe Point Road, Glebe, NSW 2037, Australia. E-mail: paul.mason@sydney.edu.au

Received: July 20 2016 | Accepted after revision: Aug 07 2016

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

References

1 Albert H, Nathavitharana RR, Isaacs C, et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J 2016; 48: 516–525.

2 Eindhoven Vooraan in de Strijd Tegen T.B.C., Koerier, 15 May 1948.

From the authors:
P.H. Mason and colleagues highlight the fact that “new technology alone cannot solve the [tuberculosis] epidemic” and that integrated and community-driven solutions are needed to meet tuberculosis (TB) care and treatment goals. The authors highlight an example of community-wide screening using portable radiography in the pre-antibiotic treatment era, with patients being prescribed rest, diet, exercise and fresh air, leading to a reduction in TB prevalence in the intervention area. We concur with the authors’ view that a focus purely on introducing new technologies, be they diagnostics, drugs or vaccines, will not have the desired impact on patient outcomes or public health. In our article, we put forward the proposition that a holistic solution is needed to ensure adequate impact of new diagnostics on patient-important outcomes [1]. For TB patients, especially those with multidrug-resistant disease, who require extremely long and arduous treatment regimens, social support, adequate diet and management of other pre-existing conditions, are essential components of a patient’s care, without which patients are unlikely to be successfully treated.

This view is also clearly reflected in the World Health Organization (WHO) End TB strategy [2] pillars: 1) integrated care and prevention (which includes treatment of comorbidities), 2) bold policies and support systems (including social protection, poverty alleviation and actions on other determinants of TB), and 3) intensified research and innovation. Importantly, intensified research and innovation encompasses development of new technologies including drugs, vaccines and diagnostics, but also innovations in implementation to optimise impact. Indeed, the WHO End TB strategy targets for decline in global TB incidence rely on the introduction of new tools, including a point-of-care test for active TB and latent TB infection, by 2025, without which global targets will remain unmet [2].

However, the continued focus on development of new tools should be matched by an equally vigorous drive towards innovation in implementation, with a strong focus on providing patient-centred care. Implementation research must address how novel diagnostics can be better integrated into healthcare...